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Background: Mesenchymal stem cells (MSCs) derived from bone marrow (BM-MSCs) and adipose tissue (AT-MSCs)
are being applied to equine cell therapy. The physiological environment in which MSCs reside is hypoxic and does
not resemble the oxygen level typically used in in vitro culture (20% O2). This work compares the growth kinetics,
viability, cell cycle, phenotype and expression of pluripotency markers in both equine BM-MSCs and AT-MSCs at 5%
and 20% O2.
Results: At the conclusion of culture, fewer BM-MSCs were obtained in hypoxia than in normoxia as a result of
significantly reduced cell division. Hypoxic AT-MSCs proliferated less than normoxic AT-MSCs because of a
significantly higher presence of non-viable cells during culture. Flow cytometry analysis revealed that the
immunophenotype of both MSCs was maintained in both oxygen conditions. Gene expression analysis using
RT-qPCR showed that statistically significant differences were only found for CD49d in BM-MSCs and CD44 in
AT-MSCs. Similar gene expression patterns were observed at both 5% and 20% O2 for the remaining surface
markers. Equine MSCs expressed the embryonic markers NANOG, OCT4 and SOX2 in both oxygen conditions.
Additionally, hypoxic cells tended to display higher expression, which might indicate that hypoxia retains
equine MSCs in an undifferentiated state.
Conclusions: Hypoxia attenuates the proliferative capacity of equine MSCs, but does not affect the phenotype
and seems to keep them more undifferentiated than normoxic MSCs.
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In recent years, mesenchymal stem cells (MSCs) have be-
come increasingly utilised in regenerative medicine and
tissue engineering applications because of their properties
for self-renewal, differentiation and immunoregulation
[1].
To study these properties, MSCs must be isolated
from their physiological niches and cultured ex vivo. The
micro-environment that cells experience in laboratory
culture is very different from their native settings; there-
fore, it is possible that the true in vivo properties of* Correspondence: rodellar@unizar.es
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reproduction in any medium, provided the orthese cells might be modified by artificial culture. One
environmental property that is commonly altered by the
change of environment is the percentage of oxygen.
Traditional incubators are supplied with atmospheric air
that contains 20% oxygen (defined as “normoxia”), which
is a not physiologically accurate for any kind of cell.
Two common MSC sources are bone marrow and adi-
pose tissue, in which the oxygen tension ranges from
1%-7% [2] and 2%-8% [3], respectively.
All nucleated cells are able to sense and respond to the
availability of O2 [4]. Rat MSCs modify the expression of
molecules involved in cell proliferation and survival
when they are exposed to low oxygen tensions that ap-
proximate physiological conditions [5]. Hypoxia indu-
cible factor 1α (HIF-1α) regulates the expression of manyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tors, such as Bcl-2 [6], and pro-apoptotic proteins, such
as p53 [7]. Consequently, rat MSCs exhibit different
proliferation rates when cell expansion under hypoxia
and normoxia are compared; however, some controversy
exists regarding whether low oxygen tension enhances
[8] or suppresses proliferation [9]. Additionally, oxygen
plays an important role in the differentiation [10] and
maintenance of stemness in MSCs [11].
Due to the inability of tendons and articulations to
heal properly, MSC-based therapies have been utilised in
horses to treat orthopaedic disorders resulting from
sporting endeavours [12,13]. Oxygen levels in cartilage
are among the lowest throughout the body [14], and
hypoxia appears to be essential for tendon repair [15]. In
addition, hypoxic preconditioning improves the thera-
peutic potential of human MSCs [16]. Taken together,
these facts suggest that horse MSCs cultured in hypoxia
might constitute a more relevant model for the treat-
ment of injuries in low-oxygen tissues than those cur-
rently utilised, which are usually cultured in 20% O2.
To improve the methodology for equine stem cell
therapy, it is necessary to examine the characteristics
and to compare the behaviour of MSCs in normoxic and
hypoxic conditions. Specifically, this study contrasts the
proliferation kinetics, viability, cell cycle progression,
phenotype and stemness of MSCs derived from bone
marrow (BM-MSCs) and adipose tissue (AT-MSCs) cul-
tured in 5% and 20% O2.
Results
Proliferation kinetics
The growth kinetics of BM- and AT-MSCs expanded
in normoxia and hypoxia were monitored for 7 days.
Normoxic MSCs derived from both sources displayed
higher number of cells than hypoxic MSCs at the end
of the culture.Figure 1 Growth kinetic curves of equine MSCs at different oxygen co
AT-MSCs (n = 6) (B). The Y axis represents the number of cells, and the X a
the means ± standard deviation. Black lines correspond to MSCs exposed tBM-MSCs exposed to both oxygen conditions showed
similar lag phase (Figure 1A); however, the log phase
lasted less in hypoxic BM-MSCs, until day 5, when they
reached a growth plateau state, while normoxic BM-
MSCs continued growing slowing down their prolifera-
tion the last day of the culture period.
Similarly to BM-MSCs, AT-MSCs at 5% and 20% O2
showed similar lag phase and the log phase ended before
in hypoxic than in normoxic AT-MSCs, which went
on the log phase until the end of the culture period
(Figure 1B). Significantly higher number of AT-MSCs in
normoxic cultures was detected on days 5 and 7.
Cell cycle
To examine the cell cycle progression under both oxy-
gen conditions, cellular DNA content was quantified in
the cultures used in the proliferation study for 7 days.
Figure 2 shows the proportions of cells in each cell cycle
phase observed in BM- and AT-MSCs expanded in nor-
moxia and hypoxia.
Cell cycle data obtained for BM-MSC cultures showed
that normoxic cells were more active than hypoxic cells
from day 2 (Table 1A). Significantly higher percentage of
normoxic BM-MSCs was observed in S phase on days 2
and 4, and in G2/M phases on day 2. Supporting this
finding, significantly higher proportion of hypoxic BM-
MSCs in G0/G1 phases was found on days 2, 3 and 4.
However, hypoxic and normoxic AT-MSCs did not dis-
play any statistically significant difference over the
course of the culture period (Table 1B).
Comparing normoxic cultures of BM-MSCs and AT-
MSCs, BM-MSCs displayed a significantly higher per-
centage of cells in G0/G1 and reduced frequency of cells
in S phase compared with AT-MSCs on days 2 and 3.
The proportions of cells in each phase of the cell cycle
were comparable throughout the remaining time course
(Table 1C).ncentrations. Growth kinetics of BM-MSCs (n = 6) (A) and
xis represents the number of days in culture. Data are represented as
o 20% O2, and grey lines to MSCs exposed to 5% O2. (*P < 0.05).
Figure 2 Cell cycle of equine BM-MSCs and AT-MSCs in normoxic and hypoxic conditions. Changes of the proportion at cell cycle phases
of normoxic BM-MSCs (A), hypoxic BM-MSCs (B), normoxic AT-MSCs (C) and hypoxic AT-MSCs (D) for 7 days. Y axis represent the percentage of
total cells and the X axis represents the culture days. Black sections represent cells in G2/M phases, grey sections represent cells in S phase and
white sections represent cells in G0/G1 phases.
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derived from both sources were more marked than in
normoxia (Table 1D). On the first day of culture, there
were significantly higher percentages of AT-MSCs in
G0/G1 phase and of BM-MSCs in S phase. However,
in the following days, until day 5, this behaviour was
inverted: significantly more BM-MSC were in G0/G1,
whereas AT-MSCs were more active in cell division
and more abundant in S phase on days 2, 4 and 5 and
in G2/M phase on days 2 and 3.
Cell viability
Possible changes in apoptosis and viability were moni-
tored in the cells used in the proliferation study during
7 days using Annexin V (AnV) and propidium iodide
(PI). Figure 3 shows the proportions of viable, apoptotic
and non-viable cells in the different cultures during the
culture period.
BM-MSCs expanded in both oxygen atmospheres
showed similar proportions of apoptotic (AnV+ PI-) and
non-viable cells (PI+) during the 7 days of culture
(Table 2A). However, on culture days 1, 2, 3 and 5, a signifi-
cantly higher proportion of viable cells was observed in
normoxic AT-MSCs than in hypoxic AT-MSCs (Table 2B).
These differences were associated with a significantly higher
frequency of PI+ cells in hypoxic conditions on days 3, 4, 5
and 7, while the proportion of AnV+ PI- cells was similar
for both conditions and never higher than 10% of the total
population.
Comparing the viability of normoxic BM-MSC and
AT-MSC culture (Table 2C), the proportions of viable
BM-MSCs were significantly higher than in AT-MSCsuntil day 3. Since then this trend reversed, being the pro-
portion of viable cells significantly higher in AT-MSCs
than in BM-MSCs on days 4 and 5. The differences in
viability between both cell types observed at early stages
of culture resulted from a significantly higher proportion
of non-viable AT-MSCs on days 1 and 2; as the time of
culture went by, the percentage of PI+ AT-MSCs became
similar and the proportion of apoptotic BM-MSCs
increased, being significantly higher on days 2, 4, 5 and 6.
The behaviour displayed by BM-MSCs and AT-MSCs
in hypoxia was similar to their normoxic equivalents
until day 4 (i.e., significantly higher percentages of PI+
and lower percentages of AnV-PI- cells were detected in
AT-MSC cultures). However, unlike normoxic MSCs,
these results were maintained until the end of the culture
period. In addition, the proportion of AnV+PI- was simi-
lar for both cell types, which contrasts with the results of
comparisons between normoxic MSCs (Table 2D).
Immunophenotype and gene expression patterns of
surface markers
The immunophenotype for the surface markers CD29
and CD90 was analysed using flow cytometry, which
revealed similar expression patterns for the MSCs inde-
pendently of source or oxygen atmosphere (Table 3). In
all cases, the percentage of positive cells was greater
than 93%.
In addition to flow cytometry, real time quantitative
PCR (RT-qPCR) was performed to assess the expression
of CD29 and CD90, as well as 8 additional surface anti-
gens (Figure 4). Few significant differences in gene ex-
pression were found between cells from the same origin
Table 1 Analysis of cell cycle in BM-MSCs (n = 6) and AT-MSCs (n = 6) cultured under hypoxic or normoxic conditions
A B C D
BM-MSC AT-MSC Normoxia Hypoxia
Normoxia Hypoxia Normoxia Hypoxia BM-MSC AT-MSC BM-MSC AT-MSC
Day 1 G0-G1 81.88 ± 15.37 78.64 ± 10.64 84.33 ± 9.48 89.04 ± 5.98 81.88 ± 15.37 84.33 ± 9.48 78.64 ± 10.64
a 89.04 ± 5.98b
S 12.51 ± 10.53 14.51 ± 7.39 9.86 ± 7.17 4.99 ± 3.12 12.51 ± 10.53 9.86 ± 7.17 14.51 ± 7.39a 4.99 ± 3.12b
G2-M 5.61 ± 5.30 6.85 ± 4.70 5.80 ± 2.42 5.74 ± 3.10 5.61 ± 5.30 5.80 ± 2.42 6.85 ± 4.70 5.74 ± 3.10
Day 2 G0-G1 49.32 ± 4.46
a 62.64 ± 5.52b 39.86 ± 3.26 41.33 ± 6.23 49.32 ± 4.46a 39.86 ± 3.26b 62.64 ± 5.5a 41.33 ± 6.23b
S 33.93 ± 6.05a 24.51 ± 5.29b 39.07 ± 1.50 35.54 ± 7.66 33.93 ± 6.05a 39.07 ± 1.50b 24.51 ± 5.29a 35.54 ± 7.66b
G2-M 17.89 ± 6.99
a 12.85 ± 3.67b 21.07 ± 3.52 23.13 ± 2,20 17.89 ± 6.99 21.07 ± 3.52 12.85 ± 3.67a 23.13 ± 2,20b
Day 3 G0-G1 56.00 ± 5.85
a 65.96 ± 5.83b 45.37 ± 3.85 51.57 ± 5.86 56.00 ± 5.85a 45.37 ± 3.85b 65.96 ± 5.83a 51.57 ± 5.86b
S 31.36 ± 8.24 22.53 ± 5.18 38.36 ± 4.49 31.42 ± 9.07 31.36 ± 8.24a 38.36 ± 4.49b 22.53 ± 5.18 31.42 ± 9.07
G2-M 12.94 ± 4.46 11.50 ± 3.31 14.60 ± 1.04 17.01 ± 6.58 12.94 ± 4.46 14.60 ± 1.04 11.50 ± 3.31
a 17.01 ± 6.58b
Day 4 G0-G1 56.30 ± 5.65
a 74.13 ± 7.11b 54.67 ± 2.64 52.74 ± 6.51 56.30 ± 5.65 54.67 ± 2.64 74.13 ± 7.11a 52.74 ± 6.51b
S 30.59 ± 10.05a 15.90 ± 6.12b 30.24 ± 1.30 26.40 ± 3.42 30.59 ± 10.05 30.24 ± 1.30 15.90 ± 6.12a 26.40 ± 3.42b
G2-M 13.00 ± 5.00 9.97 ± 4.26 14.91 ± 2.34 20.19 ± 8.15 13.00 ± 5.00 14.91 ± 2.34 9.97 ± 4.26 20.19 ± 8.15
Day 5 G0-G1 69.77 ± 11.77 79.77 ± 7.22 65.83 ± 5.76 62.63 ± 9.25 69.77 ± 11.77 65.83 ± 5.76 79.77 ± 7.22
a 62.63 ± 9.25b
S 20.16 ± 13.11 11.18 ± 4.44 22.18 ± 3.15 23.85 ± 5.48 20.16 ± 13.11 22.18 ± 3.15 11.18 ± 4.44a 23.85 ± 5.48b
G2-M 10.07 ± 2.33 9.06 ± 5.04 11.99 ± 2.75 13.55 ± 4.23 10.07 ± 2.33 11.99 ± 2.75 9.06 ± 5.04 13.55 ± 4.23
Day 6 G0-G1 75.51 ± 15.79 83.07 ± 6.31 78.36 ± 1.89 71.49 ± 11.70 75.51 ± 15.79 78.36 ± 1.89 83.07 ± 6.31 71.49 ± 11.70
S 16.08 ± 15.59 8.42 ± 3.02 13.16 ± 1.80 18.43 ± 9.18 16.08 ± 15.59 13.16 ± 1.80 8.42 ± 3.02 18.43 ± 9.18
G2-M 8.36 ± 1.67 8.35 ± 5.52 8.49 ± 1.01 10.35 ± 2.53 8.36 ± 1.67 8.49 ± 1.01 8.35 ± 5.52 10.35 ± 2.53
Day 7 G0-G1 81.71 ± 6.83 84.50 ± 8.33 85.78 ± 1.56 77.16 ± 12.67 81.71 ± 6.83 85.78 ± 1.56 84.50 ± 8.33 77.16 ± 12.67
S 15.65 ± 16.21 7.78 ± 4.03 6.73 ± 1.32 14.06 ± 9.66 15.65 ± 16.21 6.73 ± 1.32 7.78 ± 4.03 14.06 ± 9.66
G2-M 2.64 ± 2.01 7.77 ± 4.92 7.50 ± 1.26 8.78 ± 3.20 2.64 ± 2.01 7.50 ± 1.26 7.77 ± 4.92 8.78 ± 3.20
The G0/G1, S and G2/M cell cycle phases were analysed for 7 days. Cell cycle data are represented as the mean ± standard deviation. The “a” and “b” superscripted
bold data are significantly different. (A) Compares normoxic and hypoxic conditions of BM-MSCs; (B) compares normoxic and hypoxic conditions of AT-MSCs; (C)
compares BM-MSCs and AT-MSCs in normoxic conditions; and (D) compares BM-MSCs and AT-MSCs in hypoxic conditions.
Figure 3 Viability and apoptosis of equine BM-MSCs and AT-MSCs in normoxic and hypoxic conditions. Variations in the viability and
apoptosis of normoxic BM-MSCs (A), hypoxic BM-MSCs (B), normoxic AT-MSCs (C) and hypoxic AT-MSCs (D) for 7 days. Y axis represent the
percentage of total cells and the X axis represents the culture days. Black sections represent AnV+PI- cells, grey sections represent AnV-PI- cells
and white sections represent PI+ cells.
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Table 2 Viability of BM-MSCs (n = 6) and AT-MSCs (n = 6) cultured under hypoxic or normoxic conditions
A B C D
BM-MSC AT-MSC Normoxia Hypoxia
Normoxia Hypoxia Normoxia Hypoxia BM-MSC AT-MSC BM-MSC AT-MSC
Day 1 PI+ 13.64 ± 2,03 12.06 ± 3.89 46.64 ± 26.38 72.24 ± 17.20 13.64 ± 2,03a 46.64 ± 26.38b 12.06 ± 3.89a 72.24 ± 17.20b
AnV-PI- 81.92 ± 2.74 81.39 ± 8.51 47.86 ± 23.61a 21.79 ± 12.35b 81.92 ± 2.74a 47.86 ± 23.61b 81.39 ± 8.51a 21.79 ± 12.35b
AnV+PI- 4.44 ± 1.27 6.52 ± 4.94 5.60 ± 2.69 6.05 ± 6.04 4.44 ± 1.27 5.60 ± 2.69 6.52 ± 4.94 6.05 ± 6.04
Day 2 PI+ 15,02 ± 3.05 13,97 ± 6.37 28.01 ± 11.11 52.85 ± 25.16 15,02 ± 3.05a 28.01 ± 11.11b 13,97 ± 6.37a 52.85 ± 25.16b
AnV-PI- 81.91 ± 3.67 81.72 ± 7.00 65.45 ± 12.05a 39.31 ± 22.23b 81.91 ± 3.67a 65.45 ± 12.05b 81.72 ± 7.00a 39.31 ± 22.23b
AnV+PI- 3.07 ± 0.94 4.53 ± 1.52 6.54 ± 2.53 9.31 ± 5.23 3.07 ± 0.94a 6.54 ± 2.53b 4.53 ± 1.52 9.31 ± 5.23
Day 3 PI+ 15.44 ± 7.98 14.07 ± 5.08 21,29 ± 3.94a 45.97 ± 19.78b 15.44 ± 7.98 21,29 ± 3.94 14.07 ± 5.08a 45.97 ± 19.78b
AnV-PI- 77.84 ± 3.96 75.04 ± 11.65 74.28 ± 3.13a 46.24 ± 18.6b 77.84 ± 3.96a 74.28 ± 3.13b 75.04 ± 11.65a 46.24 ± 18.61b
AnV+PI- 6.71 ± 2.16 10.86 ± 7.19 4.43 ± 1.62 7.83 ± 5.23 6.71 ± 2.16 4.43 ± 1.62 10.86 ± 7.19 7.83 ± 5.23
Day 4 PI+ 14.43 ± 6.25 14.60 ± 7.41 14.64 ± 3.60a 25.39 ± 11.67b 14.43 ± 6.25 14.64 ± 3.60 14.60 ± 7.41a 25.39 ± 11.67b
AnV-PI- 76.82 ± 5.89 77.11 ± 7.49 80.98 ± 2.88 68.31 ± 11.32 76.82 ± 5.89 80.98 ± 2.88 77.11 ± 7.49 68.31 ± 11.32
AnV+PI- 8.74 ± 4.06 8.31 ± 3.15 4.41 ± 2.40 6.30 ± 5.49 8.74 ± 4.06a 4.41 ± 2.40b 8.31 ± 3.15 6.30 ± 5.49
Day 5 PI+ 8.7 ±3.27 7.34 ± 2.61 8.29 ± 1.80a 17.82 ± 7.72b 8.7 ±3.27 8.29 ± 1.80 7.34 ± 2.61a 17.82 ± 7.72b
AnV-PI- 83.03 ± 4.91 82.28 ± 8.29 89.64 ± 1.54a 77.37 ± 6.67b 83.03 ± 4.91a 89.64 ± 1.54b 82.28 ± 8.29a 77.37 ± 6.67b
AnV+PI- 8.28 ± 3.49 10.37 ± 7.60 2.06 ± 0.73 4.81 ± 4.22 8.28 ± 3.49a 2.06 ± 0.73b 10.37 ± 7.60 4.81 ± 4.22
Day 6 PI+ 8.04 ± 4.37 10.27 ± 1.59 8.64 ± 1.51 14.14 ± 8,83 8.04 ± 4.37 8.64 ± 1.51 10.27 ± 1.59 14.14 ± 8,83
AnV-PI- 84.79 ± 7.37 77.76 ± 9.44 89.18 ± 1.32 81.43 ± 10.06 84.79 ± 7.37 89.18 ± 1.32 77.76 ± 9.44 81.43 ± 10.06
AnV+PI- 7.16 ± 3.46 11.98 ± 7.96 2.14 ± 0.66 4.42 ± 2.71 7.16 ± 3.46a 2.14 ± 0.66b 11.98 ± 7.96 4.42 ± 2.71
Day 7 PI+ 9.77 ± 5,27 10.95 ± 4.29 8.05 ± 4.28a 15.69 ± 8.96b 9.77 ± 5,27 8.05 ± 4.28 10.95 ± 4.29 15.69 ± 8.96
AnV-PI- 83.29 ± 6.91 80.45 ± 5.98 85.67 ± 7.91 78.05 ± 7.77 83.29 ± 6.91 85.67 ± 7.91 80.45 ± 5.98 78.05 ± 7.77
AnV+PI- 6.92 ± 3.40 8.65 ± 7.26 6.14 ± 4.32 6.96 ± 1.16 6.92 ± 3.40 6.14 ± 4.32 8.65 ± 7.26 6.96 ± 1.16
Viability data are represented as the mean ± standard deviation. Non-viable cells (PI+), viable cells (AnV-PI-) and apoptotic cells (AnV+PI-) were analysed for 7 days.
Superscripted bold data (“a” and “b”) are significantly different. (A) Compares normoxic and hypoxic conditions of BM-MSCs; (B) compares normoxic and hypoxic
conditions of AT-MSCs; (C) compares BM-MSCs and AT-MSCs in normoxic conditions; and (D) compares BM-MSCs and AT-MSCs in hypoxic conditions.
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expression of the CD49d gene was significantly higher in
normoxic BM-MSCs than in their hypoxic counterparts.
In AT-MSCs, CD44 expression was significantly higher
in normoxia.
Further differences in gene expression were observed
when cultures from different sources exposed to the
same oxygen tension were compared. In general, there
was a trend of higher gene expression for all surfaceTable 3 Immunophenotype of BM-MSCs and AT-MSCs
cultured under normoxic and hypoxic conditions
CD29 CD90
BM-MSC Normoxia 99.73 ± 0.03 97.40 ± 0.66
BM-MSC Hypoxia 99.41 ± 0.26 98.06 ± 0.60
AT-MSC Normoxia 97.93 ± 0.83 96.52 ± 1.01
AT-MSC Hypoxia 98.75 ± 1.33 93.65 ± 3.92
Data are expressed as the mean ± standard deviation of percentages of MSCs
positive for CD29 and CD90 expression. The expression data were obtained
using flow cytometry.markers analysed in AT-MSCs, being statistically signifi-
cant for CD44, CD90 and CD105 in normoxia and
CD44, CD29, CD34, CD90 and CD146 in hypoxia. A
tendency of a higher expression in BM-MSCs was
detected for CD49d in normoxia, and CD106 in both
normoxic and hypoxic conditions. Similar gene expres-
sion patterns of the surface antigens CD73 and CD166
were detected in the four conditions (two types of cells
grown under two oxygen treatments). Although the level
of CD106 mRNA was very low in hypoxic AT-MSCs,
any significant differences existed between the two tissue
sources and oxygen conditions.
Hipoxia inducible factor 1α and pluripotency markers
The gene expression of HIF-1α and pluripotency mar-
kers was measured in both normoxic and hypoxic cells
using RT-qPCR.
Gene expression of HIF-1α was detected in BM-MSCs
and AT-MSCs in both oxygen conditions (Figure 5A).
The mRNA levels were higher in hypoxic MSCs than in
normoxic MSCs derived from the two sources, being
Figure 4 Gene expression of CD29, CD34, CD44, CD49d, CD73, CD90, CD105, CD106, CD146 and CD166 cell surface markers of equine
MSCs. Relative mRNA expression levels are expressed as the mean ± standard error. White bars correspond to normoxic BM-MSCs (n = 6), light
grey bars with hypoxic BM-MSCs (n = 6), dark grey bars with normoxic AT-MSCs (n = 6) and black bars with hypoxic AT-MSCs (n = 6). (*P < 0.05).
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AT-MSCs expressed similar levels of HIF-1α for each
oxygen condition.
Transcripts of the embryonic stem cell makers OCT4,
NANOG and SOX2 were detected in BM-MSCs and AT-Figure 5 Gene expression of the pluripotency markers in equine MSC
standard error for HIF-1α (A), OCT4 (B), NANOG (C) and SOX2 (D) . White ba
correspond to MSCs cultured under hypoxia (n = 6). *P < 0.05.MSCs expanded in both oxygen conditions (Figure 5B-D).
The mRNA levels were consistently higher in AT-MSCs
than in BM-MSCs, with statistically significant differences
for the gene expression of OCT4 in hypoxia and NANOG
in normoxia.s. Relative mRNA expression levels are expressed as the mean ±
rs correspond to MSCs cultured under normoxia (n = 6), and grey bars
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express higher levels of the three genes than the MSCs
exposed to 20% O2.
Discussion
In the equine veterinary field, orthopaedic injuries are a
major cause of retirement of athletic horses [17]. As a re-
sult, it is not surprising that equine regenerative medicine
is primarily focused on the treatment of musculoskeletal
defects. The present cell therapy studies are carried out
with MSCs [12,13,18] and non-adult stem cells [19-21].
To better understand the mechanisms of action of MSCs
in vivo, a large number of studies to characterise equine
MSCs have been reported over the last five years [22-26].
However, because the overall objective of regenerative
treatments is the use of MSCs in live horses, it is import-
ant to determine all of the properties of MSCs in an oxy-
gen environment that closely emulates the original
physiological niche from which the cells derive. To our
knowledge, the current work constitutes the first study to
perform an analysis of the influence of oxygen tension on
proliferation, viability, stemness and marker expression in
equine MSCs derived from bone marrow and adipose
tissue.
The effects of hypoxia on MSC proliferation have been
studied specifically in humans and mice. Enhancements
in cell growth following exposure to hypoxia have been
described [10,11,27]. However, there is no unanimous
consent, Feher et al. (2010) reported no difference in
the growth of normoxic and hypoxic cells, and Volker
et al. (2010) described similar numbers of cells for
both oxygen conditions at the conclusion of the cul-
ture period. In addition, Holzwarth et al. (2010), Zeng
et al. (2011) and Wang et al. (2005) reported that low
oxygen tension inhibited the proliferation of MSCs.
Similarly, canine MSCs derived from bone marrow and
adipose tissue exposed to atmospheric O2 show more pro-
liferative capacity than those expanded from passage
1 to passage 3 under hypoxic conditions (1% or 5% O2)
[28]. In agreement with these findings, our results des-
cribing the proliferation of equine cells as a function of
oxygen tension showed that the growth of AT-MSCs
was significantly higher at atmospheric oxygen tension,
while BM-MSCs underwent also more proliferation in
20% O2.
Differences in cell growth between cultures expanded
under different oxygen conditions could result from
cell cycle changes or alterations of cell viability.
Human MSC populations derived from umbilical cord
and bone marrow accumulate cells in G0/G1 phase
under low oxygen tension [9,29]. Similar to these
experiments, we found that hypoxic BM-MSCs dis-
played a higher percentage of cells in G0/G1 pha-
ses than normoxic BM-MSCs throughout the entireculture period. Moreover, the significantly higher propo-
rtion of normoxic BM-MSCs involved in the active sta-
ges of cell division (S or G2/M) during the median
days of culture led to a higher number of BM-MSCs
at the conclusion of proliferation assay in the normoxic cul-
ture. Cellular arrest in G0/G1 phase in hypoxic BM-MSCs
might be caused by up-regulation of cyclin-dependent
kinase inhibitors that control the cell cycle checkpoint
[30-32].
In contrast to BM-MSCs, differences observed in the
proliferation of normoxic and hypoxic AT-MSC cul-
tures were not due to cell cycle variations, but to varia-
tions in cell viability. Similarly to rat MSCs, that
undergo a reduction in cell viability when permanently
exposed to hypoxia [33], in our work the proportions of
viable AT-MSCs in hypoxic cultures were always lower
than those in normoxic cultures. Reduced viability in
hypoxic conditions reflects insufficient adaptation of
AT-MSCs at 5% O2, as higher percentages of non-
viable cells were found in hypoxic conditions relative to
populations at 20% O2. No detectable changes in apop-
tosis have been previously described for hypoxic MSCs
[34,35]; our results corroborate these reports since the
proportion of AnV+PI- did not display statistical diffe-
rences between normoxic and hypoxic MSCs derived
from the same source.
Moreover, AT-MSCs under either oxygen tension
adapted more poorly to the culture environment follow-
ing trypsinisation than BM-MSCs, as shown by a signifi-
cantly higher proportion of PI+ AT-MSCs at days 1 and
2 for both 5% and 20% O2 atmospheres. This is reflected
in the increased lag phase displayed by AT-MSCs. How-
ever, AT-MSCs also showed a significantly increased
proportion of cells undergoing cell division during the
first days of culture. The increase in cell division of vi-
able AT-MSCs might compensate for cell death in the
population because the final number of cells obtained at
the end of the experiment was higher in AT-MSC cul-
tures than in BM-MSC cultures, which indicates a
higher proliferative ability for AT-MSCs than BM-MSCs.
This result is in agreement with previous reports in
horses [26] and other species as canine [28], rat [36] and
human [37], which demonstrated AT-MSCs proliferated
more rapidly than BM-MSC. In our experimental condi-
tions, AT-MSCs in normoxic condition did not display a
plateau phase in the proliferation curve and, at the light
microscope, AT-MSCs start growing in several layers in-
stead of an only monolayer (data not shown). These
observations might point out a lack of contact inhibition
of growth in AT-MSCs. In addition, in a previous study,
we described the more rapid decrease of apoptosis in
AT-MSCs compared with BM-MSCs in cultures at 20%
O2 using a limited number of animals (n = 2) [26]. The
current study confirms that finding because normoxic
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apoptotic cells than normoxic BM-MSCs.
Flow cytometric immunophenotype analysis of horse
MSCs revealed that the surface antigen CD90 was detect-
able in all MSC types [38-41]. In addition, cross-reactivity
with human antibodies has been demonstrated for the
CD29 antigen in a previous report from our group and also
in other studies [42,43]. Because in other species hypoxia
does not alter the immunophenotype of MSCs with regard
to CD29 [29] and CD90 [9,27,44], we attempted to charac-
terise this phenotype in equine MSCs and to analyse the
presence of these molecules in both BM-MSCs and AT-
MSCs in hypoxia and normoxia. According to the litera-
ture, equine MSCs displayed the same immunophenotype
for CD29 and CD90 independently of the cell source and
oxygen tension.
The lack of immunoreactivity of commercial antibodies
with equine MSC antigens remains a challenge in deter-
mining the immunophenotype of these cells by flow cyto-
metry. As a supplement to this technique, RT-qPCR has
been used to establish the expression profiles of various
cell surface markers in equine MSCs [39,42]. Similar
gene expression patterns were demonstrated in AT-
MSCs when they were compared to BM-MSCs in their
respective oxygen conditions. AT-MSCs at both oxygen
tensions expressed higher levels of CD29, CD44, CD90,
CD146 and CD34 transcripts respect to BM-MSCs; in
contrast, only normoxic AT-MSCs expressed lower
mRNA levels of CD49d compared to normoxic BM-
MSCs. These results are in agreement with our previ-
ous report [43]. The differences in CD105 expression,
with respect to our previous work, might be due to in-
dividual differences because different animals were used
in the present study. Hypoxia seemed to significantly
modify mRNA levels of CD49d in BM-MSCs and CD44
in AT-MSCs, which is in agreement with other studies
that have described different expression profiles for
CD49d [45] and CD44 [46] in hypoxia. The remaining
surface markers analysed in this study showed similar
gene expression pattern at the different oxygen condi-
tions studied.
HIF-1α is a transcription factor that is expressed con-
stitutively in cells, although is ubiquitinated and
degraded under normoxic conditions. In our study, the
gene expression of this factor was detected in normoxic
and hypoxic cultures, although HIF-1α was up-regulated
in cultures exposed to low oxygen tension.
The expression of specific markers characteristic of
embryonic stem cells have been described before for
equine BM-MSCs [47] and AT-MSCs [40]. However,
to our knowledge, this is the first work that compares
the gene expression of the pluripotency markers OCT4,
NANOG and SOX2 in equine AT-MSCs and BM-MSCs
that were exposed to different oxygen concentrations. Inour experimental conditions, equine MSCs expressed all
three pluripotency markers. In general, higher expression
of each marker was detected in AT-MSCs and was
statistically significant for OCT4 in hypoxia and for
NANOG in normoxia. The consistently higher expres-
sion of all genes in hypoxia might reflect the enhanced
stemness of hypoxic equine MSCs [48]. These results
agree with other studies that have described up-re-
gulation of pluripotency-associated markers of hypoxic
MSCs [11,49,50]. To our knowledge the relationship be-
tween pluripotency markers and HIF-1α has never been
investigated in MSCs. However, studies in cancer cells
have revealed the expression of HIF-1α induces a gene
expression increase of genes involved in stemness [51];
in accordance with this, the higher expression of HIF-1α
observed in hypoxic cultures of equine MSCs could en-
hance the gene expression of the pluripotency markers.
Taken together, the results might suggest that low oxy-
gen tension helps maintain the undifferentiated stem cell
phenotype.
Conclusions
Oxygen plays a deterministic role in equine MSC cul-
tures. It is able to modify their proliferative capacity
via cell cycle modification in BM-MSCs and alterations
in cell viability in AT-MSCs. Moreover, the immuno-
phenotype of both MSC types is not altered by hyp-
oxia. However, hypoxia appears to be an important




In order to work with a homogeneous group of animals
to reduce the interindividual differences derived from
age, breed or sex, biological samples were obtained from
a total of 12 castrated male horses aged from 4 to 7 years.
All procedures were carried out under Project Licence
PI36/07, which was approved by the Ethic Committee
for Animal Experiments from the University of Zaragoza.
The care and use of animals were performed in accor-
dance with the Spanish Policy for Animal Protection
RD1201/05, which meets the European Union Directive
86/609 on the protection of animals for experimental and
other scientific purposes.
MSC isolation, culture and expansion
Samples were collected as previously described [26,43].
Briefly, bone marrow aspirates were harvested from the
sternum of six horses. The mononuclear fractions were
enriched with MSCs, which were isolated in a centrifu-
gation gradient using Lymphoprep (Atom, Barcelona,
Spain). Isolated MSCs were rinsed twice with PBS and
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medium, which consisted of DMEM Low Glucose
(Sigma-Aldrich, St. Louis, Missouri, USA) supplemented
with foetal bovine serum, L-glutamine (Sigma-Aldrich,
St. Louis, Missouri, USA) and penicillin/streptomycin
(Sigma-Aldrich, St. Louis, Missouri, USA).
Subcutaneous adipose tissues were collected from the
dorsal gluteal muscle below the tail from six horses. The
stromal vascular fractions (SVFs) were isolated by diges-
tion with 0.01% collagenase (Type I, Sigma-Aldrich, St.Table 4 Summary of gene information
Gene Accession
number
CD29 a XM_001492665 F
CD34 a XM_001491596 F:C
CD44 a NM_001085435
CD49d a XM_001917601












a previously described in [43].
b previously described in [40].
c previously described in [47].
Genes analysed, GenBank accession numbers, primer sequences for reverse transcriLouis, Missouri, USA) for 30 min at 37°C with continuous
shaking. The cells were rinsed twice with PBS and plated
in growth medium at a concentration of 105 cells/cm2.
Both MSC types were expanded for 4 weeks at 37°C in
either normoxic (5% CO2 and 20% O2) or hypoxic (5%
CO2 and 5% O2) conditions. Cell growth kinetics, immu-
nophenotype, viability and cell cycle analyses were car-
ried out using newly passaged cells fresh cells. Aliquots
of 106 cells were preserved at −150°C at the final passage,


































ptase RT-PCR (F: forward and R: reverse) and amplicon sizes in base pairs (bp).
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Cells from bone marrow and adipose tissue were seeded
in 6-well plates in triplicate at a density of 5,000 cells/
cm2. BM-MSCs (n = 6) and AT-MSCs (n = 6) were
exposed to 20% O2 or 5% O2 atmospheres for 7 days.
Every day, the cells were collected using 0.25% trypsin/
EDTA, and an aliquot of 50 μL of each culture was
counted in a haemocytometer Z2 Coulter particle count
and size analyser to obtain growth curves.Analysis of cellular DNA content
Half of the MSCs harvested from the proliferation assay
were fixed in 70% ice-cold ethanol and treated with
0.02 mg/mL RNAse and EDTA. DNA was stained with
0.1 mg/mL propidium iodide (Sigma-Aldrich, St. Louis,
Missouri, USA). Cells were incubated in the dark for
30 min, and samples were analysed on a FACSARRAY
(BD Biosciences, East Rutherford, New Jersey, USA) cyt-
ometer using the MODIFIT 3.0 software.Viability assay
The remaining fraction of MSCs harvested in the prolif-
eration assay was used to determine MSC viability.
Apoptosis was measured by the detection of phosphati-
dylserine on the outer leaflet of the plasma membrane
with the fluorescent dye Annexin V-FITC (Immunostep,
Salamanca, Spain) in accordance with the manufacturer’s
instructions. Briefly, cells were rinsed with ice-cold PBS
and then resuspended in 200 μL of binding buffer. Subse-
quently, 10 μL of Annexin V stock solution was added to
cells and incubated for 30 min at 4°C. Non-viable cells
were identified by incubation with 5 μL of propidium
iodide, a dye that penetrates into the cell nucleus when
the plasma and nuclear cell membranes are damaged. PI-
stained cells were immediately analysed in a FACSARIA
cytometer (BD Biosciences, East Rutherford, New Jersey,
USA) using FACSDIVA 5.0.1 software.Immunophenotyping
To determine the immunophenotype of BM-MSCs and
AT-MSCs after hypoxic and normoxic culture, the ex-
pression of the MSC surface markers CD29 (Integrin β1)
and CD90 (Thy-1) was assessed by flow cytometry as
previously described [43] using mouse anti-human
monoclonal antibodies CD29-FITC (Caltag Laboratories,
Little Balmer, Buckingham, UK) and CD90-PE (BD Phar-
mingen, San Diego, California, USA.). Negative control
staining was performed using a FITC-conjugated mouse
IgG1 isotype and a PE-conjugated mouse isotype. The
immunophenotype was determined with the cytometer
and software described above.Gene expression analysis
The expression of 10 genes encoding cell surface mole-
cules, including CD29 and CD90, was determined by
real-time quantitative PCR. Additional antigens exam-
ined were CD34, CD44 (H-CAM), CD49d (α4 integrin),
CD73 (ecto-5’-nuclease), CD105 (endoglin), CD106
(VCAM 1), CD146 (MCAM) and CD166 (ALCAM). The
gene expression levels of the pluripotency markers
OCT4, SOX2 and NANOG were also analysed using the
same technique.
Total RNA was extracted using the RNA spin mini (GE
Healthcare Lifesciences, Little Chalfont, UK) and DNAse
turbo (Ambion, Foster City, California, USA.) kits; subse-
quently, the Superscript kit (Invitrogen, Carlsbad, CA,
USA ) was used for reverse transcription of 1.5 μg of total
RNA into complementary DNA. All kits were used in ac-
cordance with the manufacturer’s instructions.
Table 4 shows the names of the analysed genes, Gen-
Bank accession numbers for equine mRNA sequences,
forward and reverse primer sequences and amplicon
sizes. Amplifications were performed in triplicate using
the Fast SYBR Green Master Mix reagent (Applied Bio-
systems, Foster City, California, USA) and the StepOne™
Real Time System (Applied Biosystems, Foster City, Cali-
fornia, USA). The levels of gene expression were deter-
mined using the comparative Ct method. A normalisation
factor was calculated as the geometric mean of the quan-
tity of two housekeeping genes (GAPDH and B2M) and
used to normalise the expression of each gene.
Statistical analyses
The software SPSS 19.0 (Armonk, Nueva York, USA)
was used to perform statistical analyses. Data obtained
from flow cytometry and RT-qPCR were analysed for
normality with the Shapiro-Wilk test. Differences in
gene expression and reactivity levels in BM- and AT-
MSCs expanded under hypoxia and normoxia conditions
were determined using unpaired non-parametric Mann–
Whitney tests. Differences in proliferation, viability and
cell cycle were evaluated with Student’s t-test. For both
tests, P < 0.05 was considered statistically significant.
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